The Centers for Disease Control and Prevention (CDC) estimates about 600,000 people die of heart disease each year in the United States, comprising one in every four deaths. The annual financial cost stands at more than $108.9 billion for healthcare, medication and loss related to productivity.
When you look at the numbers related to heart disease, it can be overwhelming and at times discouraging, but fantastic improvements in prevention, medication and less invasive surgical procedures are producing promising results. A report from healthcare experts at GlobalData reveals just how effective and promising one of these surgical procedures has become.
The report examined Transchatheter Aortic Valve Replacement (TAVR) in severe Aortic Valve Disease (AVD).
TAVR eliminates the need for open heart surgery and the trauma and long recuperative time associated with the procedure. The surgery is made by implanting a prosthetic aortic valve in the damaged valve. In most patients, the new valve is inserted through the groin with a delivery catheter specially designed for this procedure.
Using x-ray, the valve is guided to the desired location and the aortic valve can be replaced without stopping the heart or making an incision. Patients with femoral artery disease can have the procedure done by making a small incision between the ribs.
"AVD affects over 3.6 percent of the population older than 65, and severe cases of it have mortality rates of nearly 50 percent at two years. However, even after 45 years of refinement, surgical techniques fail to provide suitable options for AVD patients who are inoperable due to comorbidities. Since its first in-human use in 2002, TAVR has created a wholly new market targeted at this inoperable crowd,” said Rob Littlefield, MSc., GlobalData’s analyst for cardiovascular devices.
The report points out the potential of TAVR as it becomes more accepted globally in treating AVD. Germany is leading the way with this procedure performing more than 8,000 operations in 2011. Other European countries as well as the U.S. are seeing the benefits of this procedure after positive clinical studies. Markets in Asia, South America, Australia and South Africa have just started using the procedure and the device.
While trials are on the way in Japan, some heart centers in Singapore are already using the device, and South America approved a TAVR company to introduce their product.
The companies the report looked at include:
- AorTech
- Boston Scientific
- Bracco Sp
- Braile Biomedica
- Colibri
- Direct Flow
- Edwards Lifesciences
- Hansen
- JenaValve
- Medtronic
- Perouse
- St. Jude
- Symetis
- Transcatheter Technologies
- ValveXchange
According to GlobalData, its forecast for TAVR is expected to have a global reach of $2.8 billion by 2018. The report provides detailed information about TAVR Device Market covering patients, doctors, policy, companies and future trends.
Edited by
Braden Becker
